relative to health care cost transparency.
HB 705 creates a new “Transparency in Coverage” subdivision within New Hampshire’s managed care law requiring health plans to publicly disclose detailed pricing information for covered health care items and services. The bill applies to all health plans and requires them to post three machine-readable files on a public website: one for in-network rates, one for out-of-network allowed amounts and billed charges, and one for prescription drug pricing, including negotiated rates and historical net prices. The disclosures must include standardized identifiers and billing codes, provider information, contract dates, and other data needed to compare prices across plans and providers.
The bill also requires health plans to submit the same pricing information to the insurance commissioner in a standardized format, and directs the commissioner to compile and publish the data through an online comparison tool. The reporting must be updated monthly, and the public files must be accessible free of charge without login or personal information. The bill includes definitions for key pricing terms, allows delegation of disclosure duties to third parties such as administrators or clearinghouses, and provides good-faith compliance protections for errors, temporary website outages, and reliance on information from others. Its main operative provisions apply to plan years beginning on or after January 1, 2026, but only after federal guidance under Presidential Executive Order 14221 is finalized, with implementation delayed six months after that guidance is issued.
HB 705 would amend RSA 420-J by adding a new transparency subdivision that imposes broad disclosure and reporting obligations on health plans, including carriers, third-party administrators, and other entities subject to claims data submission requirements. It would require new public-facing machine-readable files, monthly updates, and standardized reporting to the insurance commissioner, while preserving existing privacy and security requirements. The bill would affect health plans, insurers, administrators, pharmacy benefit-related arrangements, providers whose rates are disclosed, and consumers seeking price comparison information.
The available record suggests generally favorable or at least noncontroversial treatment of the bill, as reflected by its adoption by both bodies and the absence of recorded committee testimony or vote opposition in the provided materials. The bill’s stated purpose—health care cost transparency and easier price comparison—appears aligned with consumer-facing policy goals. No dissenting remarks, recorded roll-call votes, or committee transcript excerpts were provided to indicate significant opposition.
The main potential points of contention are administrative burden, data standardization, and privacy/compliance issues. Health plans must collect, format, and update extensive pricing data monthly, including provider-specific negotiated rates, out-of-network allowed amounts, and prescription drug historical net prices, which may be costly and operationally complex. The bill also raises questions about how much information can be disclosed without violating health information privacy laws, and it conditions implementation on final federal guidance under Executive Order 14221, indicating that conformity with federal standards is a key issue. Another possible concern is reliance on third parties for data submission, since the bill leaves the health plan ultimately responsible for enforcement even when disclosure functions are delegated.